Chemotherapy Events Immunization 
pharmaphorum
SEPTEMBER 11, 2022
With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”
European Pharmaceutical Review
OCTOBER 25, 2024
The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 31, 2022
In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.
pharmaphorum
NOVEMBER 29, 2022
Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. No serious adverse events were observed.
Pharmaceutical Technology
SEPTEMBER 13, 2022
The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. Overall survival (OS) data remains immature, with too few events for statistical analysis.
European Pharmaceutical Review
DECEMBER 28, 2023
Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.
Hospital Pharmacy Europe
OCTOBER 20, 2023
Administered as an intravenous infusion, it works by encouraging healthy immune cells in the body to destroy the cancer cells. The most common adverse event was cytokine release syndrome (CRS) (63%). Discontinuation of glofitamab due to adverse events occurred in 9% of the patients.
Expert insights. Personalized for you.
105 
Let's personalize your content